A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression
Latest Information Update: 08 May 2025
At a glance
- Drugs Empagliflozin (Primary) ; Vicadrostat (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 17 Apr 2025 New trial record